Trial of Hypofractionated Radiation Therapy for Glioblastoma

Exclusion Criteria

• •1. Recurrent or multifocal malignant gliomas. Multicentric gliomas, defined as multiple, discrete areas of enhancement on T1 weighted MRI sequences with contrast all contained within one connected region of abnormality on T2 weighted/FLAIR MRI sequences, are allowed to enroll on this study.
• •2. Prior invasive malignancy (except for non-melanomatous skin cancer) unless expected survival from prior malignancy is ≥ 5 years.
• •3. Prior head or neck RT (except for T1 glottic cancer), or systemic therapy precluding delivery of concurrent and adjuvant temozolomide
• •4. Treatment with any other therapeutic clinical protocol within 30 days prior to study registration or during participation in the study.
• •5. Severe, active co-morbidity, defined as follows:
• •1. Unstable angina and/or congestive heart failure requiring hospitalization
• •2. Transmural myocardial infarction within the last 6 months
• •3. Acute bacterial or fungal infection requiring intravenous antibiotics at the time of study registration
• •4. Any severe, active co-morbidity precluding delivery of temozolomide.
• •6. Women of child-bearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception.
• •7. Pregnant or lactating women, due to possible adverse effects on the developing fetus or infant due to temozolomide.